|Articles|February 1, 2012
Christine Moore Bio
<-- -->
Advertisement
Christine Moore Bio
Dr. Moore is the currently the Acting Director of FDA's Office of New Drug Quality Assessment. Christine has been with the FDA since 2004 and has been at the forefront of FDA's Quality by Design efforts including being a member of the expert working group for ICH Q8(R). Prior to joining the FDA, she worked for 10 years in API process development and scale-up at Pfizer and Searle/Pharmacia. Her background is in chemical and biochemical engineering, with degrees from Northwestern University and Massachusetts Institute of Technology.
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Europe Tried to Ban Generative AI From Critical GMP. The Ban May Not Survive. It Does Not Matter.
2
PharmTech Weekly Roundup—August 14, 2026
3
Q&A: Why Is Halo Pharma Expanding Into Sterile Injectables Now?
4
What Does TAUKLARIFY's Approval Mean for Alzheimer's Drug Developers?
5
